text: .@US_FDA announced their decision to grant accelerated approval for a treatment from Sarepta Therapeutics to treat Duchenne Muscular Dystrophy. This is a great advance in therapies for DMD that target the root cause of the disease. https://t.co/GsxvsARPyj